Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Carol M. Antequera, Kimberly Orleck, Rinu Jacob, Amy Kenneally & Wendy L. Wright. (2024) Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori. Postgraduate Medicine 136:2, pages 131-140.
Read now
Read now
M. Hojo, H. Miwa, A. Nagahara, N. Sato. (2001) Pooled Analysis on the Efficacy of the Second-line Treatment Regimens for Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology 36:7, pages 690-700.
Read now
Read now
I. Adamsson, C. Edlund & C.E. Nord. (2000) Microbial Ecology and Treatment of Helicobacter pylori Infections: Review. Journal of Chemotherapy 12:1, pages 5-16.
Read now
Read now
Articles from other publishers (23)
Matt Shirley. (2024) Vonoprazan: A Review in Helicobacter pylori Infection. Drugs 84:3, pages 319-327.
Crossref
Crossref
Carmelo Scarpignato, Colin W. Howden, Eckhard Leifke, Darcy J. Mulford, Gezim Lahu, Axel Facius & Richard Hunt. (2023)
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and
Helicobacter pylori
infection
. Alimentary Pharmacology & Therapeutics 58:1, pages 16-25.
Crossref
Crossref
Svetlana Serebrova, Daria Kurguzova, Lyudmila Krasnykh, Galina Vasilenko, Vladimir Drozdov, Natalia Lazareva, Eugenia Shikh, Marina Zhuravleva, Svetlana Rykova, Natalia Eremenko, Elena Kareva, Karin Mirzaev, Dmitriy Sychev & Alexey Prokofiev. (2022)
Potential factors of
Helicobacter pylori
resistance to clarithromycin
. Drug Metabolism and Personalized Therapy 37:4, pages 383-391.
Crossref
Crossref
Young Woon Chang, Weon Jin Ko, Chi Hyuk Oh, Yoo Min Park, Shin Ju Oh, Jung Rock Moon, Jun-Hyung Cho, Jung-Wook Kim & Jae-Young Jang. (2019) Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. The Korean Journal of Internal Medicine 34:5, pages 1022-1029.
Crossref
Crossref
Jihee SungNayoung KimYo Han ParkYoung Jae HwangSoohoon KwonGyeongjae NaJoon Young ChoiJae Bin KangHye Rang KimJin-Wook KimDong Ho Lee. (2017)
Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for
Helicobacter pylori
Eradication Failure
. The Korean Journal of Gastroenterology 69:2, pages 109.
Crossref
Crossref
Elizabeth A. Marcus, George Sachs & David R. Scott. (2016) Eradication of Helicobacter pylori Infection. Current Gastroenterology Reports 18:7.
Crossref
Crossref
Maria Pina Dore, Hong Lu & David Y Graham. (2016)
Role of bismuth in improving
Helicobacter pylori
eradication with triple therapy
. Gut 65:5, pages 870-878.
Crossref
Crossref
David R. Scott, George Sachs & Elizabeth A. Marcus. (2016) The role of acid inhibition in Helicobacter pylori eradication. F1000Research 5, pages 1747.
Crossref
Crossref
Ju Yup Lee, Nayoung Kim, Min Soo Kim, Yoon Jin Choi, Jung Won Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee & Hyun Chae Jung. (2014) Factors Affecting First-Line Triple Therapy of Helicobacter pylori Including CYP2C19 Genotype and Antibiotic Resistance. Digestive Diseases and Sciences 59:6, pages 1235-1243.
Crossref
Crossref
Jyh‐Chin Yang, Hong‐Long Wang, Herng‐Der Chern, Chia‐Tung Shun, Bor‐Ru Lin, Chun‐Jung Lin & Teh‐Hong Wang. (2012)
Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole‐Amoxicillin Dual Therapy for
Helicobacter pylori
Eradication
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:3, pages 227-238.
Crossref
Crossref
David Y. Graham, Syed Ussama Javed, Sara Keihanian, Suhaib Abudayyeh & Antone R. Opekun. (2010) Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. Journal of Gastroenterology 45:8, pages 816-820.
Crossref
Crossref
T. Shimatani, M. Moriwaki, J. Xu, S. Tazuma & M. Inoue. (2006) Acid-suppressive effects of rabeprazole: Comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Digestive and Liver Disease 38:11, pages 802-808.
Crossref
Crossref
Javier P. Gisbert, Antonio Dominguez-Munoz, Antonio Dominguez-Martin, Jose Luis Gisbert & Santiago Marcos. (2005) Esomeprazole-Based Therapy in Helicobacter pylori Eradication: Any Effect by Increasing the Dose of Esomeprazole or Prolonging the Treatment?. The American Journal of Gastroenterology 100:9, pages 1935-1940.
Crossref
Crossref
Tomohiko Shimatani, Masaki Inoue, Tomoko Kuroiwa, Jing Xu, Susumu Tazuma, Yoko Horikawa & Masuo Nakamura. (2005) Acid-Suppressive Efficacy of a Reduced Dosage of Rabeprazole: Comparison of 10 Mg Twice Daily Rabeprazole with 20 Mg Twice Daily Rabeprazole, 30 Mg Twice Daily Lansoprazole, and 20 Mg Twice Daily Omeprazole by 24-Hr Intragastric pH-metry. Digestive Diseases and Sciences 50:7, pages 1202-1206.
Crossref
Crossref
Javier P Gisbert. (2005) Potent Gastric Acid Inhibition in Helicobacter pylori Eradication. Drugs 65:Supplement 1, pages 83???96.
Crossref
Crossref
J. P. Gisbert, S. Khorrami, X. Calvet, R. Gabriel, F. Carballo & J. M. Pajares. (2003)
Meta‐analysis: proton pump inhibitors vs. H
2
‐receptor antagonists — their efficacy with antibiotics in
Helicobacter pylori
eradication
. Alimentary Pharmacology & Therapeutics 18:8, pages 757-766.
Crossref
Crossref
D. Pantoflickova, G. Dorta, M. Ravic, P. Jornod & A. L. Blum. (2003) Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Alimentary Pharmacology & Therapeutics 17:12, pages 1507-1514.
Crossref
Crossref
F. Perri, M. R. Villani, V. Festa, M. Quitadamo & A. Andriulli. (2002)
Predictors of failure of
Helicobacter pylori
eradication with the standard ‘Maastricht triple therapy’
. Alimentary Pharmacology & Therapeutics 15:7, pages 1023-1029.
Crossref
Crossref
Joachim Labenz. (2001) Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Practice & Research Clinical Gastroenterology 15:3, pages 413-431.
Crossref
Crossref
S. P. Kaushik & C. Vu. (2008)
Helicobacter pylori
eradication with lansoprazole, amoxycillin and clarithromycin: testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication
. Australian and New Zealand Journal of Medicine 30:2, pages 231-235.
Crossref
Crossref
Inger Adamsson, Carl Erik Nord, Per Lundquist, Svante Sjöstedt & Charlotta Edlund. (1999) Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. Journal of Antimicrobial Chemotherapy 44:5, pages 629-640.
Crossref
Crossref
H. Miwa, R. Ohkura, T. Murai, K. Sato, A. Nagahara, S. Hirai, S. Watanabe & N. Sato. (2001)
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for
Helicobacter pylori
infection—comparison with omeprazole and lansoprazole
. Alimentary Pharmacology & Therapeutics 13:6, pages 741-746.
Crossref
Crossref
Mary K Stamatakis & Paula Jo Meyer-Stout. (1999) Disintegration performance of renal multivitamin supplements. Journal of Renal Nutrition 9:2, pages 78-83.
Crossref
Crossref